• BBy

  Participated · Equity · May 2023

  BBy sells a patent-pending device and process that converts donor breast milk into shelf-stable powder that retains nutritional and immunological properties and remains stable for up to six months. The company packages powdered milk in one- and two-ounce aluminum packets and delivers to hospitals every two weeks, removing freezer needs and reducing waste. BBy processes roughly 10 gallons of breast milk twice daily across eight regional processing facilities serving 17 client hospitals, with a main research facility in Guadalajara, Mexico. The U.S. FDA has designated BBy’s technology as a food device and does not require further medical review. The company is averaging about $800,000 in revenue per month (approaching $10 million annually) and expects to double revenue in the next year as hospital contracts close. Future product plans mentioned include developing more user-friendly versions of the device for individual use, though current focus remains on hospitals.

• KayoThera

  Participated · Series A · Mar 2022

  KayoThera is developing first-in-class, oral small-molecule inhibitors that target the retinoid pathway. The platform originated from biology discovered at Princeton University by Mark Esposito and Yibin Kang. The company is advancing lead programs in diabetes and oncology, including therapies for late-stage and metastatic cancers. KayoThera states the additional resources will support IND-enabling safety studies and position programs for strategic partnering. To date the company has secured $14 million in total financial support, comprised of equity and non-dilutive grant funding. Recent grants include NIH SBIR awards (NIDDK and NCI) and funding from the Andy Hill Cancer Research Endowment (CARE) Fund. KayoThera is an early-stage therapeutics company developing a new class of cancer immunotherapies grounded in research from Princeton University. The company was co-founded in 2019 by Mark Esposito and Yibin Kang and has identified a family of key enzymes targetable with novel small molecule inhibitors. KayoThera is advancing a lead oncology program aimed at treating late-stage and metastatic cancers, including breast, lung, pancreatic, colorectal, brain, and kidney cancers. The firm plans to move its lead program toward the clinic to translate its discoveries into therapies for patients with advanced disease. Leadership includes Dr. Esposito as Vice President of Research and Development and Dr. Kang as Chair of the Scientific Advisory Board. Financially, KayoThera received initial backing from Foundation Venture Capital Group and has recently closed a Series A to fund development.

No current team members are available.